Edgewise Therapeutics Financials - Benzinga

Edgewise Therapeutics Inc

EWTXNASDAQ

Trade with Public

Trade with Public

$40.84

-1.92-4.5%

Last update: Aug 31, 11:36 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Edgewise Therapeutics Financials

Edgewise Therapeutics (EWTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Edgewise Therapeutics Q2 EPS $(0.53) Misses $(0.47) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.47) by 12.77 percent. This is a 55.88 percent decrease over losses of $(0.34) per

Benzinga Newsdesk

PRO
Edgewise Therapeutics Q1 EPS $(0.46) Beats $(0.50) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.50) by 8 percent. This is a 6.98 percent decrease over losses of $(0.43) per share from

Benzinga Newsdesk

PRO
Edgewise Therapeutics Q4 EPS $(0.47) Misses $(0.43) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.05 percent. This is a 11.9 percent decrease over losses of $(0.42) per share

Benzinga Newsdesk

Gold Edges Lower; Omeros Shares Jump

Avi Kapoor

PRO
Edgewise Therapeutics Q3 EPS $(0.39) Beats $(0.40) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.40) by 1.76 percent. This is a 14.71 percent decrease over losses of $(0.34) per share

Benzinga Newsdesk

PRO
Edgewise Therapeutics Q2 EPS $(0.34) Beats $(0.43) Estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.43) by 20.19 percent. This is unchanged from the same period last year.

Benzinga Newsdesk